Physician

Muhammad Sohail Ghani, MD

According to 2025 Medicare claims, Muhammad Ghani, MD (NPI: 1427055045) practices hematology/oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89052-9998.

Ghani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 492 traditional Medicare patients, billed 126,433 HCPCS/CPT codes, and received $1,858,075 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,201 prescription claims across 163 beneficiaries totaling $1,697,853 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 166 records totaling $3,403. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $850,172 to $1,858,075. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,427,530 and ending at $1,697,853. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $514 and ending at $970.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	735	70,925	$850,172
2016	839	113,356	$1,155,149
2017	354	49,651	$784,153
2018	349	68,146	$1,081,039
2019	405	108,161	$1,532,182
2020	419	101,186	$1,536,295
2021	477	118,976	$1,391,895
2022	516	131,705	$1,966,031
2023	507	117,173	$1,604,733
2024	492	126,433	$1,858,075

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	304	1,679	$1,427,530
2016	397	1,947	$1,507,220
2017	367	2,165	$2,182,393
2018	254	1,736	$1,730,904
2019	192	1,354	$1,174,045
2020	137	1,074	$1,107,257
2021	145	933	$1,092,078
2022	163	1,112	$1,179,712
2023	149	1,171	$934,372
2024	163	1,201	$1,697,853

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	50	$38,859
2016	N/R	75	$31,616
2017	N/R	54	$14,930
2018	N/R	76	$8,041
2019	N/R	30	$4,751
2020	N/R	20	$1,069
2021	N/R	60	$2,246
2022	N/R	22	$2
2023	N/R	26	$513
2024	N/R	11	$1

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	265	899	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	192	298	$66
80053	Blood test, comprehensive group of blood chemicals	220	739	$10
36415	Insertion of needle into vein for collection of blood sample	293	958	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	287	1,075	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	25	700	$552,051
Imbruvica	Ibrutinib	21	598	$309,074
Eliquis	Apixaban	36	2,640	$49,996
Xarelto	Rivaroxaban	26	1,260	$24,150
Trexall	Methotrexate Sodium	15	532	$4,763

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	N	N/R	11	$1

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	166	$3,403	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad Sohail Ghani, MD?

Tedicare shows public-source Medicare data for Muhammad Sohail Ghani, MD (NPI 1427055045), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad Sohail Ghani, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Muhammad Sohail Ghani, MD?

Muhammad Sohail Ghani, MD is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Muhammad Sohail Ghani, MD have Open Payments data?

Muhammad Sohail Ghani, MD has 166 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.